Skip to main content

Bresch testifies to Oversight committee, defends EpiPen's price

Mylan CEO Heather Bresch fielded questions on the cost of EpiPen, her own compensation, her mother's involvement in getting the auto-injectors in schools nationwide, and the company's profits during a hearing Wednesday before the U.S. House Committee on Oversight and Government Reform.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.